null

Anti-SMYD1 Antibody (CAB2340)

SKU:
CAB2340
Product Type:
Antibody
Reactivity:
Human
Mouse
Rat
Host Species:
Rabbit
Isotype:
IgG
Research Area:
Epigenetics and Nuclear Signaling
  • Epigenetics and Nuclear Signaling Antibodies 3 Anti-SMYD1 Antibody CAB2340
  • Epigenetics and Nuclear Signaling Antibodies 3 Anti-SMYD1 Antibody CAB2340
  • Epigenetics and Nuclear Signaling Antibodies 3 Anti-SMYD1 Antibody CAB2340
  • Epigenetics and Nuclear Signaling Antibodies 3 Anti-SMYD1 Antibody CAB2340
  • Epigenetics and Nuclear Signaling Antibodies 3 Anti-SMYD1 Antibody CAB2340
$167 - $503
Frequently bought together:

Description

system_update_altDatasheetsystem_update_altMSDS

Anti-SMYD1 Antibody (CAB2340)

The SMYD1 Polyclonal Antibody (CAB2340) is formulated for research involving SMYD1, a protein involved in the regulation of muscle development and function. This antibody, generated in rabbits, exhibits high specificity and reactivity towards SMYD1 in human samples, making it a reliable tool for Western blot applications. By binding to the SMYD1 protein, this antibody enables accurate detection and analysis in a variety of cell types, rendering it ideal for investigations in the fields of muscle biology and disease research.SMYD1, also known as SET and MYND domain-containing protein 1, is a key player in myogenesis, the process by which muscle cells differentiate and mature. Its crucial role in muscle formation and maintenance makes it a valuable target for studies on muscular disorders, cardiac diseases, and muscular dystrophies.

Understanding the function of SMYD1 is essential for developing therapeutic strategies that can enhance muscle regeneration and prevent muscle-related disorders.Overall, the SMYD1 Polyclonal Antibody (CAB2340) serves as a valuable tool for researchers seeking to explore the biological functions and mechanisms of SMYD1 in various physiological and pathological contexts. Its high specificity and sensitivity make it an indispensable asset in advancing our understanding of muscle biology and developing targeted therapies for muscle-related conditions.